Targeted SARS-CoV-2 Variant Sequencing via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for SARS-CoV-2 variants, such as Alpha, Beta, Delta, and Omicron, are time-consuming and costly, posing challenges in rapid and effective identification, especially in emergency situations and resource-limited settings.
Innovation Solution
A method involving sequencing a nucleic acid with at least 80% identity to a specific sequence (positions 76 to 645 of SEQ ID NO. 1) to identify nucleotide replacements and deletions, allowing for the rapid and cost-effective detection of SARS-CoV-2 variants, using a single sequencing reaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genomic sequencing is performed to identify SARS-CoV-2 variants, then variant identification accuracy is improved, but processing time and cost increase
Solution Approach 1:
The patent segments the SARS-CoV-2 genome into specific regions of interest (such as the spike protein gene) and focuses sequencing efforts on these critical segments rather than performing complete whole-genome sequencing. This segmentation allows for rapid identification of variant-defining mutations while significantly reducing processing time and cost compared to comprehensive genomic sequencing.
Solution Approach 2:
The patent extracts and sequences only the specific nucleic acid regions that contain variant-defining mutations (such as positions 76-645 of SEQ ID NO. 1). By extracting and analyzing only these critical regions rather than the entire genome, the method achieves accurate variant identification with reduced processing time and resource requirements.
2Reliability
If comprehensive genomic sequencing is performed to detect all SARS-CoV-2 variants, then detection reliability is improved, but cost increases
Solution Approach 1:
The patent extracts and sequences only the specific nucleic acid regions that contain variant-defining mutations (such as positions 76-645 of SEQ ID NO. 1). By extracting and analyzing only these critical regions rather than the entire genome, the method achieves accurate variant identification with reduced processing time and resource requirements.
Solution Approach 2:
The patent designs a universal sequencing approach that can detect multiple SARS-CoV-2 variants (Alpha, Beta, Delta, Gamma, and emerging variants) using the same targeted region and methodology. This multi-functional approach maintains high detection reliability across all variants while reducing costs compared to variant-specific testing protocols.
3Speed
If rapid sequencing methods are used to reduce processing time, then speed is improved, but measurement precision may deteriorate
Solution Approach 1:
The patent segments the SARS-CoV-2 genome into specific regions of interest (such as the spike protein gene) and focuses sequencing efforts on these critical segments rather than performing complete whole-genome sequencing. This segmentation allows for rapid identification of variant-defining mutations while significantly reducing processing time and cost compared to comprehensive genomic sequencing.
Solution Approach 2:
The patent optimizes sequencing parameters (such as cycle sequencing conditions, primer concentrations, and thermal cycling profiles) to achieve high-fidelity nucleotide identification within a reduced time frame. By carefully adjusting these parameters, the method maintains measurement precision while improving sequencing speed.
Data Source
AI summary
The present invention concerns methods for detecting SARS-CoV 2 virus omicron, alpha, beta, delta and/or gamma as well as kits for performing such methods.